These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37942534)

  • 21. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
    Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of BMP6 is associated with its methylation status in colorectal cancer tissue but lacks prognostic significance.
    Sangplod P; Kanngurn S; Boonpipattanapong T; Ruangrat P; Sangkhathat S
    Asian Pac J Cancer Prev; 2014; 15(17):7091-5. PubMed ID: 25227796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
    Cheetham S; Tang MJ; Mesak F; Kennecke H; Owen D; Tai IT
    Br J Cancer; 2008 Jun; 98(11):1810-9. PubMed ID: 18458674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
    Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
    Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping of DNA Hypermethylation and Hypomethylation induced by Folate Deficiency in Sporadic Colorectal Cancer and Clinical Implication Analysis of Hypermethylation Pattern in CBS Promoter.
    Zhang Z; He Y; Tu X; Huang S; Chen Z; Wang L; Song J
    Clin Lab; 2017 Apr; 63(4):733-748. PubMed ID: 28397458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
    Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
    PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial-mesenchymal transition via inhibiting MDM2.
    Wang X; Li Y; Pan M; Lu T; Wang M; Wang Z; Liu C; Hu G
    Clin Sci (Lond); 2022 Nov; 136(22):1691-1710. PubMed ID: 36377775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter methylation and expression of SOCS-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer.
    Kang XC; Chen ML; Yang F; Gao BQ; Yang QH; Zheng WW; Hao S
    Biomed Pharmacother; 2016 May; 80():23-29. PubMed ID: 27133036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Semaphorin-3F functions as a tumor suppressor in colorectal cancer due to regulation by DNA methylation.
    Gao X; Tang C; Shi W; Feng S; Qin W; Jiang T; Sun Y
    Int J Clin Exp Pathol; 2015; 8(10):12766-74. PubMed ID: 26722466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer.
    Rawluszko AA; Bujnicka KE; Horbacka K; Krokowicz P; Jagodziński PP
    BMC Cancer; 2013 Nov; 13():526. PubMed ID: 24195777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer.
    Namba S; Sato K; Kojima S; Ueno T; Yamamoto Y; Tanaka Y; Inoue S; Nagae G; Iinuma H; Hazama S; Ishihara S; Aburatani H; Mano H; Kawazu M
    Cancer Sci; 2019 Mar; 110(3):1096-1104. PubMed ID: 30637877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
    Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
    Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.
    Wang Y; He T; Herman JG; Linghu E; Yang Y; Fuks F; Zhou F; Song L; Guo M
    Clin Epigenetics; 2017; 9():115. PubMed ID: 29075358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
    Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
    PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells.
    Gisina A; Novikova S; Kim Y; Sidorov D; Bykasov S; Volchenko N; Kaprin A; Zgoda V; Yarygin K; Lupatov A
    Cancer Biomark; 2021; 32(1):85-98. PubMed ID: 34092615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylation status of T-lymphoma invasion and metastasis 1 promoter and its overexpression in colorectal cancer.
    Jin H; Li T; Ding Y; Deng Y; Zhang W; Yang H; Zhou J; Liu C; Lin J; Ding Y
    Hum Pathol; 2011 Apr; 42(4):541-51. PubMed ID: 21237486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
    Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells.
    Habano W; Gamo T; Terashima J; Sugai T; Otsuka K; Wakabayashi G; Ozawa S
    BMC Cancer; 2011 Feb; 11():81. PubMed ID: 21342487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.